KINNATE BIOPHARMA INC KNTE
COM · Common Stock · CUSIP 49705R105
0
institutional holders
-57 vs Q1 2024
—reported value*
0 new
0 added
0 reduced
56 sold out
net sold ≈ $91.9m (-34.5m shares)
* Summed across managers. Shares that two managers' reports both contain – a subsidiary's holdings that its parent's report includes too, or a sub-adviser's in its client's – are counted once. Holder counts are more reliable.
Trends to Q2 2024
Institutional holders
Managers reporting a position, each quarter
Numbers
| Quarter | Holders |
|---|---|
| Q3 2022 | 84 |
| Q4 2022 | 80 |
| Q1 2023 | 72 |
| Q2 2023 | 73 |
| Q3 2023 | 60 |
| Q4 2023 | 63 |
| Q1 2024 | 57 |
| Q2 2024 | 0 |
Buyers vs sellers
Managers adding to or starting a position, vs cutting or selling out
Bought or addedCut or sold out
Numbers
| Quarter | Bought or added | Cut or sold out |
|---|---|---|
| Q4 2022 | 30 | 39 |
| Q1 2023 | 32 | 35 |
| Q2 2023 | 41 | 51 |
| Q3 2023 | 24 | 43 |
| Q4 2023 | 33 | 29 |
| Q1 2024 | 26 | 38 |
| Q2 2024 | 0 | 56 |
Calls vs puts
Options held, notional value, last 4 quarters. P/C = puts ÷ calls
CallsPuts
Numbers
| Quarter | Calls | Puts | P/C |
|---|---|---|---|
| Q3 2023 | $29.6k | $3.1k | 0.10 |
| Q4 2023 | $20.0k | $4.8m | 241.54 |
| Q1 2024 | $254.4k | $5.5m | 21.54 |
| Q2 2024 | $0 | $0 | — |
Biggest buyers
| None |
Biggest sellers
| Foresite Capital Management IV, LLC | Sold out | -9.7m |
| ORBIMED ADVISORS LLC | Sold out | -8.0m |
| Foresite Capital Management V, LLC | Sold out | -3.5m |
| Lynx1 Capital Management LP | Sold out | -2.0m |
| VIKING GLOBAL INVESTORS LP | Sold out | -1.8m |
| VANGUARD GROUP INC | Sold out | -1.1m |
| DELTEC ASSET MANAGEMENT LLC | Sold out | -1.0m |
| TANG CAPITAL MANAGEMENT LLC | Sold out | -977.6k |
| ACADIAN ASSET MANAGEMENT LLC | Sold out | -964.9k |
| RENAISSANCE TECHNOLOGIES LLC | Sold out | -887.7k |
Holders, Q2 2024
| Manager | Shares | Change |
|---|